ImmunoGen (IMGN) Reports Q3 Loss, Misses Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.26% and -53.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Leave a comment

Your email address will not be published. Required fields are marked *